Colorectal LLM Wiki

Browse
Home / Sources / ASCRS Ch30 - Colorectal Cancer Postoperative Adjuvant Therapy and Surveillance
Source created 2026-08-25 · updated 2026-08-25
colorectalrectal-cancercolon-canceradjuvant-chemotherapysurveillancetextbook

ASCRS Ch30 - Colorectal Cancer Postoperative Adjuvant Therapy and Surveillance

Chapter 30 of the ASCRS Textbook of Colon and Rectal Surgery, 4th edition (Kleiman DA, Larson DW). Book pp. 529–545. Thirtieth chapter overall (first of the textbook's dedicated postoperative-management content following Chapters 24–29's staging/neoadjuvant/surgical-treatment sequence for colon and rectal cancer).

Covers two linked but distinct topics: (1) postoperative adjuvant chemotherapy/radiotherapy for colon and rectal cancer following curative-intent resection, and (2) surveillance strategy after curative-intent therapy. Textbook reference chapter — not primary literature; individual cited trials (MOSAIC, NSABP C-07, IDEA collaboration, ADORE, German CAO/ARO/AIO-04, AVANT, PETACC-8, N0147, ACOSOG Z6041, FACS, GILDA, COLOFOL, CEA Watch, PRODIGE 13) are named and their headline results reported, but none are independently ingested from primary publications.

Key content

  • Colon cancer adjuvant chemotherapy: Stage III standard-of-care evolution (5-FU/leucovorin → oxaliplatin-based FOLFOX/CAPOX per MOSAIC and NSABP C-07) and the IDEA duration-collaboration risk-stratified 3-vs-6-month recommendation (2020 NCCN guidelines). Stage II: Table 30.1 high-risk features, MSI/MMR/BRAF risk stratification, multigene assays (Oncotype DX).
  • Radiation for colon cancer: very limited role (radiation enteritis risk); one negative RCT; NCDB/SEER data showing no OS/DSS benefit from adjuvant radiation even in T4 colon cancer with a close/positive margin.
  • Neoadjuvant chemotherapy/radiation for colon cancer: FOxTROT data (tumor downstaging, fewer positive margins, no morbidity increase) — closely corroborates content already on Colon Cancer Resection from ASCRS Ch25 - Colon Cancer Surgical Treatment.
  • Rectal cancer adjuvant therapy — three scenarios: adjuvant chemotherapy following neoadjuvant radiation (ADORE, German CAO/ARO/AIO-04, a ~1200-patient meta-analysis showing no OS/DFS/distant- recurrence benefit from postoperative FOLFOX after neoadjuvant CRT — yet 2020 NCCN still recommends adjuvant chemotherapy regardless of final histology, due to conflicting/limited data); adjuvant therapy without neoadjuvant radiation (postoperative radiation morbidity, two historical RCTs establishing adjuvant chemoradiation's benefit over surgery/radiation alone, current NCCN stage- based recommendations); adjuvant therapy following local excision of early-stage rectal cancer (Table 30.2 high-risk features, ACOSOG Z6041 3-year DFS 87%, current NCCN local-excision-adjuvant recommendations).
  • Targeted chemotherapy options: AVANT (bevacizumab), PETACC-8 and N0147 (cetuximab) — all three trials negative for adjuvant benefit, with added toxicity.
  • Molecular profiling: MMR/MSI and BRAF (V600E) testing for risk stratification and chemotherapy-benefit prediction; Oncotype DX 12-gene recurrence-score assay (risk-stratifies but doesn't predict adjuvant-therapy response).
  • Surveillance after curative-intent therapy: extensive discussion of recurrence terminology, lead-time/stage-migration bias, Table 30.3 (national-society surveillance-guideline comparison: ASCO 2013, ESMO 2013, ESMO 2017, NCCN 2020 colon, NCCN 2020 rectum, ASCRS 2015), historical trial evidence (8 RCTs 1995–2014, Tjandra & Chan and Pita-Fernandez meta-analyses), modern trial evidence (Table 30.4: FACS, GILDA, COLOFOL, plus CEA Watch and the ongoing PRODIGE 13 trial — all showing no significant survival benefit from intensive surveillance), the Alliance/Commission-on-Cancer NCDB collaboration, a 2019 Cochrane-adjacent systematic review, and real-world surveillance-compliance data. Specific-test detail: physical exam, CEA, abdominal imaging, colonoscopy (including metachronous-neoplasia and second-primary-cancer rates). Special circumstances: Stage I colon cancer (endoscopic surveillance only) and Stage I rectal cancer (local-site surveillance emphasis given 4–33% local-recurrence risk after local excision — ERUS/MRI every 3–6 months for 2 years then every 6 months for a total of 5, extending beyond 5 years given regrowths reported past 7 years). Quality-of-life and cost sections. Conclusion: the evidence base increasingly favors less-intensive surveillance, with US guidelines lagging behind that evidence.

Wiki integration

Backs two new concept pages — Adjuvant Chemotherapy for Colorectal Cancer and Colorectal Cancer Surveillance After Curative Treatment — and enriches Rectal Cancer's existing Survival/surveillance/adjuvant-chemotherapy section, Colon Cancer Resection (light corroboration), and Local Excision of Rectal Neoplasms (Table 30.2 high-risk features and the ACOSOG Z6041 3-year DFS figure).